Jan A Burger
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jan A Burger as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:37 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04505254 · Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center · active not recruiting · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- Ph2NCT04458610 · Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaM.D. Anderson Cancer Center · active not recruiting · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · principal investigator
- Ph2NCT02007044 · Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center · active not recruiting · Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma · principal investigator
- Ph1/Ph2NCT01752426 · Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLLM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT01520519 · Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma PatientsM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph1/Ph2NCT01160354 · Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)M.D. Anderson Cancer Center · terminated · Acute Myelogenous Leukemia · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 25 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:37 UTC. The ranking covers the 200 most relevant of 64 PubMed records, and a shared surname and initials can bring in a namesake. All 64 on PubMed
- Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.N Engl J Med · 20131,919 citationsRCR 50.1
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.N Engl J Med · 20151,350 citationsRCR 39.6
- 456 citationsRCR 10.0
- Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.Am J Hematol · 2019421 citationsRCR 16.4
- 404 citationsRCR 17.1
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.Lancet Oncol · 2014400 citationsRCR 11.0
- 341 citationsRCR 11.0
- 311 citationsRCR 12.0
- Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.Lancet Oncol · 2014294 citationsRCR 7.7
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.Lancet Haematol · 2020282 citationsRCR 11.3